CN107998080A - 一种偶联抗体的主动靶向载药长循环脂质体及其制备方法 - Google Patents
一种偶联抗体的主动靶向载药长循环脂质体及其制备方法 Download PDFInfo
- Publication number
- CN107998080A CN107998080A CN201711164104.6A CN201711164104A CN107998080A CN 107998080 A CN107998080 A CN 107998080A CN 201711164104 A CN201711164104 A CN 201711164104A CN 107998080 A CN107998080 A CN 107998080A
- Authority
- CN
- China
- Prior art keywords
- liposome
- antibody
- oxaliplatin
- monoclonal antibody
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 65
- 230000008685 targeting Effects 0.000 title claims abstract description 23
- 239000003814 drug Substances 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 229960001756 oxaliplatin Drugs 0.000 claims abstract description 50
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims abstract description 50
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 24
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 17
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 12
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims abstract description 9
- 230000002137 anti-vascular effect Effects 0.000 claims abstract description 9
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 34
- 239000000243 solution Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 13
- 150000003904 phospholipids Chemical class 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 229940044683 chemotherapy drug Drugs 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 6
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 5
- 230000008014 freezing Effects 0.000 claims description 5
- 238000007710 freezing Methods 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 239000012074 organic phase Substances 0.000 claims description 5
- 238000002390 rotary evaporation Methods 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 238000010257 thawing Methods 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 17
- 230000008878 coupling Effects 0.000 abstract description 6
- 238000010168 coupling process Methods 0.000 abstract description 6
- 238000005859 coupling reaction Methods 0.000 abstract description 6
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract description 4
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 abstract 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 description 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 3
- 230000003527 anti-angiogenesis Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 238000002679 ablation Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 210000002767 hepatic artery Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000001656 angiogenetic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种偶联抗体的主动靶向载药长循环脂质体及其制备方法。该靶向长循环脂质体包括抗体、化疗药和脂质体;所述的抗体为抗血管内皮生长因子单克隆抗体;所述的化疗药物为奥沙利铂;所述的长循环脂质体包含磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺‑聚乙二醇2000。抗体偶联奥沙利铂脂质体,其制备原料含有磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺‑聚乙二醇2000、新型抗血管内皮生长因子单克隆抗体(抗VEGF单克隆抗体)和抗肿瘤药物奥沙利铂。目前已获得初步结果,抗体偶联率为43.76%,抗体的活性保持为84.16%,表明这种主动靶向脂质体可有效与血管内皮生长因子特异性结合,从而达到减毒增效的作用。
Description
技术领域
本发明涉及一种主动靶向载药长循环脂质体技术,属于医药制备的技术领域。
背景技术
目前肝细胞癌是我国高发和常见的恶性肿瘤,发病率和死亡率均居全球之首。虽有多种治疗手段,包括外科手术、局部消融、肝动脉介入、化疗以及放疗等,但能够手术者仅有15%,而在临床上大多数肝细胞癌在确诊时已达中晚期,局部消融、肝动脉介入和药物治疗成为主要的姑息治疗手段,但是改善生存的作用有限。因此,迫切需要寻找新的突破性治疗手段。
肿瘤生长与血管生成密切相关,选择参与血管生成过程的重要因子或关键环节作为靶点,可以靶向调控肿瘤的生长和转移,达到治疗肿瘤的目的。抗血管内皮生长因子(VEGF)及其受体(VEGFR)是促进肿瘤血管生成的重要靶分子,与肿瘤的发生、发展密切相关。而肝细胞癌为典型的富血管恶性肿瘤,肿瘤细胞大量分泌VEGF,并通过自分泌和旁分泌两种途径促进肿瘤生长和血管生成,本发明选择抗VEGF单克隆抗体为主动靶向纳米制剂的靶头,同时此种单抗也可以通过中和肿瘤部位的VEGF,达到抗肿瘤细胞增殖和抗血管生成作用。
奥沙利铂是继顺铂和卡铂之后的第三代铂类衍生物,是临床上治疗胃肠道肿瘤的常见药物,其作用机制是在细胞内产生烷化结合物与DNA形成链内和链外交联,抑制DNA的合成和复制,产生细胞毒作用和抗肿瘤活性。近年一项大型临床研究(EACH研究)结果表明,含奥沙利铂联合化疗方案治疗亚洲晚期肝细胞癌患者安全有效,可为肝细胞癌患者带来病情的局部控制和生存获益。但是,剂量限制性毒性大大制约了奥沙利铂临床疗效的发挥。因此,迫切需要寻找新的剂型来提高奥沙利铂的疗效,减少其毒副作用,为患者带来更好的治疗途径。
目前关于奥沙利铂脂质体的研究较为广泛,但尚未见抗血管内皮生长因子单克隆抗体偶联奥沙利铂脂质体的相关研究报道。本发明采用抗VEGF单克隆抗体偶联奥沙利铂脂质体,既能有效提高奥沙利铂的生物利用度,减少其毒副反应,又能实现发挥单抗靶向和抗肿瘤双重作用。
发明内容
技术问题:为了充分利用抗VEGF单克隆抗体的靶向作用和抗血管生成作用,以及提高奥沙利铂药物的生物利用度并减轻毒副作用,本发明提供一种偶联抗体的主动靶向载药长循环脂质体及其制备方法将抗VEGF单克隆抗体偶联到奥沙利铂脂质体上,使其构成新型主动靶向纳米制剂。
技术方案:本发明的一种偶联抗体的主动靶向载药长循环脂质体,该靶向长循环脂质体包括抗体、化疗药和脂质体;所述的抗体为抗血管内皮生长因子单克隆抗体;所述的化疗药物为奥沙利铂;所述的长循环脂质体包含磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000。
其中,
所述的抗血管内皮生长因子单克隆抗体为抗VEGF单克隆抗体。
所述的抗体、化疗药和脂质体的质量比为:0.2-0.5:0.1-0.4:15。
所述的磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000的质量比为:
3-5:1:0.5-1.25。
本发明的偶联抗体的主动靶向载药长循环脂质体的制备方法为:
步骤1,称取磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000、磷脂-聚乙二醇2000-马来酰亚胺溶于氯仿中,得到氯仿混合溶液,
步骤2,然后称取奥沙利铂原料药溶于5%葡萄糖溶液中,
步骤3,在探头超声下,将步骤2得到的溶有奥沙利铂的葡萄糖溶液缓慢滴加到步骤1得到的氯仿混合溶液中,形成均一稳定的W/O型乳液,水相与有机相体积为1:3,
步骤4,然后在45℃下减压旋蒸蒸发除去氯仿,得到脂质体溶液,
步骤5,将步骤4得到的脂质体溶液在-20℃至室温条件下冻融2-5次,通过0.4-0.1μm碳酸脂膜6-8次即得载奥沙利铂长循环脂质体,
步骤6,将单抗和2-亚氨基硫烷盐酸盐混合于EP管中,室温条件下,置于低速摇床,反应1-2h,得到巯基化的单抗,
步骤7,将步骤6得到的巯基化的单抗与上述制备好的奥沙利铂脂质体于4-55℃孵育得到偶联单抗的奥沙利铂脂质体。
所述的单抗与2-亚氨基硫烷盐酸盐,按照摩尔比为1:100-200混合。
有益效果:为了充分利用抗VEGF单克隆抗体的靶向作用和抗血管生成作用,以及提高奥沙利铂药物的生物利用度并减轻毒副作用,将抗VEGF单克隆抗体偶联到奥沙利铂脂质体上,使其构成新型主动靶向纳米制剂。
本发明制备得到的主动靶向脂质体呈淡蓝色乳液,透射电镜表明脂质体主要呈类圆球形;电泳验证抗体与脂质体偶联成功;抗体偶联率约为43.76%;酶联免疫活性实验结果表明抗体的活性保持约为84.16%。表明抗体偶联率较高,且活性保持较完整。
附图说明
图1:抗血管内皮生长因子单克隆抗体偶联载药脂质体的结构图。
具体实施方式
本发明的偶联抗体的主动靶向载药长循环脂质体,主要由抗体、化疗药和脂质体组成;所述的抗体为抗血管内皮生长因子单克隆抗体;所述的化疗药为奥沙利铂;所述的长循环脂质体包含磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000。充分利用单抗的靶向作用和抗血管生成作用,以及提高奥沙利铂药物的生物利用度并减轻毒副作用,本发明将单抗偶联到奥沙利铂脂质体上,使其构成新型主动靶向纳米制剂。
实例1、精密称取适量磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000、磷脂-聚乙二醇2000-马来酰亚胺(质量比为4:1:1:0.4)溶于氯仿中,然后称取适量的奥沙利铂原料药溶于5%葡萄糖溶液中。在探头超声下,将溶有奥沙利铂的溶液缓慢滴加到氯仿中,形成均一稳定的W/O型乳液,水相:有机相体积为1:3。然后在45℃下减压旋蒸除去氯仿得到脂质体溶液,接着将脂质体溶液冻融3次,通过0.2μm碳酸脂膜8次即得载奥沙利铂长循环脂质体。将单抗和2-亚氨基硫烷盐酸盐按照摩尔比为1:200混合于EP管中,室温条件下,置于低速摇床,反应2h,得到巯基化的单抗。然后将其与上述制备好的奥沙利铂脂质体于4℃过夜孵育得到偶联单抗的奥沙利铂脂质体。
实例2、精密称取适量的磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000、磷脂-聚乙二醇2000-马来酰亚胺(质量比为4:1:0.6:0.4)溶于氯仿中,然后称取适量的奥沙利铂原料药溶于5%葡萄糖溶液中。在探头超声下,将溶有奥沙利铂的溶液缓慢滴加到氯仿中,形成均一稳定的W/O型乳液,水相:有机相体积为1:3。然后在45℃下减压旋蒸除去氯仿得到脂质体溶液,接着将脂质体溶液冻融3次,通过0.2μm碳酸脂膜6次即得载奥沙利铂长循环脂质体。将单抗和2-亚氨基硫烷盐酸盐按照摩尔比为1:100混合于EP管中,室温条件下,置于低速摇床,反应2h,得到巯基化的单抗。然后将其与上述制备好的奥沙利铂脂质体于4℃过夜孵育得到偶联单抗的奥沙利铂脂质体。
实例3、精密称取适量的磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000、磷脂-聚乙二醇2000-马来酰亚胺溶于氯仿(质量比为5:1:0.8:0.4)中,然后称取适量的奥沙利铂原料药溶于5%葡萄糖溶液中。在探头超声下,将溶有奥沙利铂的溶液缓慢滴加到氯仿中,形成均一稳定的W/O型乳液,水相:有机相体积为1:3。然后在45℃下减压旋蒸除去氯仿得到脂质体溶液,接着将脂质体溶液冻融3次,通过0.2μm碳酸脂膜8次即得载奥沙利铂长循环脂质体。将单抗和2-亚氨基硫烷盐酸盐按照摩尔比为1:200混合于EP管中,室温条件下,置于低速摇床,反应2h,得到巯基化的单抗。然后将其与上述制备好的奥沙利铂脂质体于55℃孵育10min得到偶联单抗的奥沙利铂脂质体。
Claims (6)
1.一种偶联抗体的主动靶向载药长循环脂质体,其特征在于,该靶向长循环脂质体包括抗体、化疗药和脂质体;所述的抗体为抗血管内皮生长因子单克隆抗体;所述的化疗药物为奥沙利铂;所述的长循环脂质体包含磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000。
2.根据权利要求1所述的偶联抗体的主动靶向载药长循环脂质体,其特征在于,所述的抗血管内皮生长因子单克隆抗体为抗VEGF单克隆抗体。
3.根据权利要求1所述的偶联抗体的主动靶向载药长循环脂质体,其特征在于,所述的抗体、化疗药和脂质体的质量比为:0.2-0.5:0.1-0.4:15。
4.根据权利要求1所述的偶联抗体的主动靶向载药长循环脂质体,其特征在于,所述的磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000的质量比为:3-5:1:0.5-1.25。
5.一种如权利要求1所述的偶联抗体的主动靶向载药长循环脂质体的制备方法,其特征在于,该制备方法为:
步骤1,称取磷脂、胆固醇、二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000、磷脂-聚乙二醇2000-马来酰亚胺溶于氯仿中,得到氯仿混合溶液,
步骤2,然后称取奥沙利铂原料药溶于5%葡萄糖溶液中,
步骤3,在探头超声下,将步骤2得到的溶有奥沙利铂的葡萄糖溶液缓慢滴加到步骤1得到的氯仿混合溶液中,形成均一稳定的W/O型乳液,水相与有机相体积为1:3,
步骤4,然后在45℃下减压旋蒸蒸发除去氯仿,得到脂质体溶液,
步骤5,将步骤4得到的脂质体溶液在-20℃至室温条件下冻融2-5次,通过0.4-0.1μm碳酸脂膜6-8次即得载奥沙利铂长循环脂质体,
步骤6,将单抗和2-亚氨基硫烷盐酸盐混合于EP管中,室温条件下,置于低速摇床,反应1-2h,得到巯基化的单抗,
步骤7,将步骤6得到的巯基化的单抗与上述制备好的奥沙利铂脂质体于4-55℃孵育得到偶联单抗的奥沙利铂脂质体。
6.根据权利要求5所述的偶联抗体的主动靶向载药长循环脂质体的制备方法,其特征在于,所述的单抗与2-亚氨基硫烷盐酸盐,按照摩尔比为1:100-200混合。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711164104.6A CN107998080A (zh) | 2017-11-21 | 2017-11-21 | 一种偶联抗体的主动靶向载药长循环脂质体及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201711164104.6A CN107998080A (zh) | 2017-11-21 | 2017-11-21 | 一种偶联抗体的主动靶向载药长循环脂质体及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107998080A true CN107998080A (zh) | 2018-05-08 |
Family
ID=62053157
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201711164104.6A Pending CN107998080A (zh) | 2017-11-21 | 2017-11-21 | 一种偶联抗体的主动靶向载药长循环脂质体及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107998080A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109316447A (zh) * | 2018-06-18 | 2019-02-12 | 上海大学 | 功能基化的脂质体及其制备方法及应用 |
WO2020042996A1 (zh) * | 2018-08-29 | 2020-03-05 | 中国科学院上海药物研究所 | 奥沙利铂偶联前药、其制备方法及用途 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101015699A (zh) * | 2007-01-17 | 2007-08-15 | 东南大学 | 聚乙二醇-磷脂酰乙醇胺聚合物或它的药用酸加成盐及在制药中的应用 |
CN101103972A (zh) * | 2007-07-13 | 2008-01-16 | 陈祥峰 | 一种奥沙利铂脂质体葡萄糖制剂及其制备方法、应用 |
WO2008123685A1 (en) * | 2007-04-04 | 2008-10-16 | Postech Academy-Industry Foundation | Liposome sensitive to ph or reductive condition and method of preparing the same |
US20100239657A1 (en) * | 2006-11-09 | 2010-09-23 | Mogam Biotechnology Research Institute | Composite for liver-specific delivery and release of therapeutic nucleic acids or drugs |
CN103269722A (zh) * | 2010-09-24 | 2013-08-28 | 马林克罗特有限公司 | 治疗性和/或诊断性纳米载体的靶向的适体缀合物 |
CN103520207A (zh) * | 2013-10-23 | 2014-01-22 | 上海交通大学医学院附属仁济医院 | 靶向性顺铂纳米海藻酸钠脂质体 |
CN104258425A (zh) * | 2014-09-17 | 2015-01-07 | 东南大学 | 一种rgd修饰的超小磁性氧化铁纳米颗粒的制备方法及其应用 |
CN107308458A (zh) * | 2017-06-20 | 2017-11-03 | 国家纳米科学中心 | 一种靶向性杂化纳米体系及其制备方法和应用 |
-
2017
- 2017-11-21 CN CN201711164104.6A patent/CN107998080A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100239657A1 (en) * | 2006-11-09 | 2010-09-23 | Mogam Biotechnology Research Institute | Composite for liver-specific delivery and release of therapeutic nucleic acids or drugs |
CN101015699A (zh) * | 2007-01-17 | 2007-08-15 | 东南大学 | 聚乙二醇-磷脂酰乙醇胺聚合物或它的药用酸加成盐及在制药中的应用 |
WO2008123685A1 (en) * | 2007-04-04 | 2008-10-16 | Postech Academy-Industry Foundation | Liposome sensitive to ph or reductive condition and method of preparing the same |
CN101103972A (zh) * | 2007-07-13 | 2008-01-16 | 陈祥峰 | 一种奥沙利铂脂质体葡萄糖制剂及其制备方法、应用 |
CN103269722A (zh) * | 2010-09-24 | 2013-08-28 | 马林克罗特有限公司 | 治疗性和/或诊断性纳米载体的靶向的适体缀合物 |
CN103520207A (zh) * | 2013-10-23 | 2014-01-22 | 上海交通大学医学院附属仁济医院 | 靶向性顺铂纳米海藻酸钠脂质体 |
CN104258425A (zh) * | 2014-09-17 | 2015-01-07 | 东南大学 | 一种rgd修饰的超小磁性氧化铁纳米颗粒的制备方法及其应用 |
CN107308458A (zh) * | 2017-06-20 | 2017-11-03 | 国家纳米科学中心 | 一种靶向性杂化纳米体系及其制备方法和应用 |
Non-Patent Citations (4)
Title |
---|
SERGEY A. SHEIN ETAL: "VEGF- and VEGFR2-Targeted Liposomes for Cisplatin Delivery to Glioma Cells", 《MOLECULAR PHARMACEUTICS》 * |
张奇编: "《军用药物制剂工程学》", 30 April 2012, 北京理工大学出版社 * |
杨闯: "抗VEGFR2-奥沙利铂免疫脂质体对结直肠癌靶向治疗的研究", 《中国博士学位论文全文数据库(医药卫生科技辑)》 * |
赵雁等: "奥沙利铂聚乙二醇修饰脂质体的制备及其大鼠体内的药动学", 《中国医药工业杂志》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109316447A (zh) * | 2018-06-18 | 2019-02-12 | 上海大学 | 功能基化的脂质体及其制备方法及应用 |
WO2020042996A1 (zh) * | 2018-08-29 | 2020-03-05 | 中国科学院上海药物研究所 | 奥沙利铂偶联前药、其制备方法及用途 |
CN110872324A (zh) * | 2018-08-29 | 2020-03-10 | 中国科学院上海药物研究所 | 奥沙利铂偶联前药、其制备方法及用途 |
CN110872324B (zh) * | 2018-08-29 | 2021-09-14 | 中国科学院上海药物研究所 | 奥沙利铂偶联前药、其制备方法及用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mulier et al. | Survival benefit of adding Hyperthermic IntraPEritoneal Chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence | |
Wang et al. | Precise engineering of prodrug cocktails into single polymeric nanoparticles for combination cancer therapy: extended and sequentially controllable drug release | |
CN107921248A (zh) | 用于向肿瘤更佳地递送活性剂的方法 | |
BR112018012641A2 (pt) | molécula de penetração de célula portadora de fármaco, métodos para facilitar a incorporação de um composto biologicamente ativo (bac) em uma célula, para melhorar a biodisponibilidade de um fármaco ou bac, para introduzir um fármaco ou bac em um sítio e para alterar a expressão de um gene endógeno ou exógeno, e, composição. | |
CN107998080A (zh) | 一种偶联抗体的主动靶向载药长循环脂质体及其制备方法 | |
EP2920187B1 (en) | A method of using binuclear gold(i) compounds for cancer treatment | |
CN109069500A (zh) | 一种用于治疗胃癌的喹啉衍生物 | |
CN104888234A (zh) | 纳米-金属有机骨架化合物负载siRNA在制备抗肿瘤药物中的应用 | |
CN103585135B (zh) | 厚朴酚在制备治疗恶病质及癌症的药物中的应用 | |
CN110041375A (zh) | 具有不对称单取代萘酰亚胺四价铂结构的化合物、制备方法及其在制备抗肿瘤药物中的应用 | |
CN108524533A (zh) | 一种化合物用作抗肿瘤药物增效剂和逆转剂 | |
CN113979954B (zh) | 一种替尼类抗肿瘤药物化合物及其制备方法和应用 | |
Shah et al. | Intersection of inorganic chemistry and nanotechnology for the creation of new cancer therapies | |
BR112021007287A2 (pt) | vesículas extracelulares para terapias direcionadas contra células supressoras derivadas de mieloide | |
CN110664784B (zh) | 一种复合纳米给药系统及其在妇科肿瘤治疗中的应用 | |
CN104804047B (zh) | 新型含氮氧自由基的二茂铁衍生物的制备方法及其用途 | |
Shahrivar et al. | Smart Lipid‐Based Nanoparticles in Lung Cancer Treatment: Current Status and Future Directions | |
Jeremić et al. | Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (Stage III) non-small-cell lung cancer: single institution experience with 600 patients | |
JP5774013B2 (ja) | シクロデキストリンのデオキシポドフィロトキシン包接錯体、その調製法、および癌治療への使用 | |
JP7311177B2 (ja) | A-NOR-5αアンドロスタン薬物と抗がん薬物との併用 | |
US20220280469A1 (en) | Pharmaceutical compound and preparation method therefor and use thereof | |
CN106902097A (zh) | 一种可改善药物生物利用度的药物组合物 | |
CN101289453B (zh) | 鞣花酸化合物的制备方法 | |
CN101653607B (zh) | 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途 | |
CN102058879B (zh) | 一种口服肿瘤纳米疫苗及其构建方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180508 |
|
RJ01 | Rejection of invention patent application after publication |